GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Durect Corp (NAS:DRRX) » Definitions » Gross Margin %

Durect (Durect) Gross Margin %

: 75.35% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Durect's Gross Profit for the three months ended in Dec. 2023 was $2.01 Mil. Durect's Revenue for the three months ended in Dec. 2023 was $2.67 Mil. Therefore, Durect's Gross Margin % for the quarter that ended in Dec. 2023 was 75.35%.

Warning Sign:

Durect Corp gross margin has been in long-term decline. The average rate of decline per year is -2.2%.


The historical rank and industry rank for Durect's Gross Margin % or its related term are showing as below:

DRRX' s Gross Margin % Range Over the Past 10 Years
Min: 62.28   Med: 86.26   Max: 95.33
Current: 79.91


During the past 13 years, the highest Gross Margin % of Durect was 95.33%. The lowest was 62.28%. And the median was 86.26%.

DRRX's Gross Margin % is ranked better than
91.83% of 991 companies
in the Drug Manufacturers industry
Industry Median: 46.83 vs DRRX: 79.91

Durect had a gross margin of 75.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Durect was -2.20% per year.


Durect Gross Margin % Historical Data

The historical data trend for Durect's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durect Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.96 95.33 86.01 91.76 79.91

Durect Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.46 81.11 82.75 82.11 75.35

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Durect's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durect Gross Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Durect's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Durect's Gross Margin % falls into.



Durect Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Durect's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=6.8 / 8.548
=(Revenue - Cost of Goods Sold) / Revenue
=(8.548 - 1.717) / 8.548
=79.91 %

Durect's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=2 / 2.669
=(Revenue - Cost of Goods Sold) / Revenue
=(2.669 - 0.658) / 2.669
=75.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Durect  (NAS:DRRX) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Durect had a gross margin of 75.35% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Durect Gross Margin % Related Terms

Thank you for viewing the detailed overview of Durect's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durect (Durect) Business Description

Traded in Other Exchanges
Address
10260 Bubb Road, Cupertino, CA, USA, 95014
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Executives
Judith J. Robertson director 10260 BUBB ROAD, CUPERTINO CA 95014
Gail J Maderis director 364 LOMBARD ST., SAN FRANCISCO CA 94133
Timothy M. Papp officer: Chief Financial Officer C/O DURECT CORPORATION, 10260 BUBB ROAD, CUPERTINO CA 95014
Gail M Farfel director 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Mohammad Azab director C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Peter S Garcia director ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Norman Sussman officer: Chief Medical Officer C/O DURECT CORP., 10260 BUBB ROAD, CUPERTINO CA 95014
Bleichroeder Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, NEW YORK NY 10105
Judy R Joice officer: Sr. VP Operations & Corp QA 10260 BUBB ROAD, CUPERTINO CA 95014
21 April Fund Lp 10 percent owner 1345 AVENUE OF THE AMERICAS, 47TH FLOOR, New York NY 10105
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Michael Arenberg officer: Chief Financial Officer 10260 BUBB ROAD, CUPERTINO CA 95014
James E Brown director, officer: President & CEO 10240 BUBB RD, CUPERTINO CA 95014
First Eagle Investment Management, Llc 10 percent owner 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105